TPO and autoimmune thrombocytopenic purpura: However, patients failing ITP first‐line therapy represent an unmet clinical need, and new therapeutic strategies compatible with ART are necessary and crucial: thrombopoietin receptor agonists (TPO‐RAs) may be useful [10, 11], but the indication of some TPO‐RAs in clinical practice is often strictly limited because of interaction with ART.